Skip to main content
OpenTrials
Completed

NCT Number: NCT01100385

TomVasc - Vascular Effects of Tomato Extract

Does tomato extract improve blood vessel function in healthy people and people with cardiovascular disease?

Atherosclerosis ('furring' of the arteries) affects the functioning of blood vessels, narrowing and eventually blocking them, causing conditions like heart attack and stroke. The Mediterranean diet, which is rich in tomatoes and tomato-based products, has been shown to be associated with a reduced risk of blood vessel damage. In this double blind, placebo-controlled randomised study, the investigators will investigate whether a food supplement containing a standardised extract of tomato improves blood vessel function in both healthy people (aged 40-80), and people with a history of cardiovascular disease. The food supplement is on sale to the public, and the investigators are testing the standard dose. Approximately 72 people will take part at the Clinical Pharmacology Unit at the ACCI Building, Cambridge University Hospitals NHS Trust.

After they have passed screening tests, participants will be allocated by chance to receive either the tomato extract product (Ateronon), or a matching placebo (a dummy capsule with no active ingredients), which they will take once a day for 8 weeks. At the beginning and end of the treatment period, the investigators will test blood vessel stiffness using an ECG machine and external probe. The investigators will also measure forearm blood flow, which involves infusing 3 separate agents that affect how the lining of the blood vessel wall works, and helps to assess whether this is affected by the study treatment. Blood tests will also be used to look at how the food supplement is working and its effects on cholesterol and markers of inflammation. Including the screening period, and a follow-up telephone call two weeks after the end of treatment, participants will be in the study for 14 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Addenbrooke's Hospital

Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

HEALTHY GROUP

Inclusion criteria

  • Aged between 30 and 80 years
  • Non-smoking

Exclusion criteria

  • Hypertension or other cardiovascular disease
  • Significant renal, respiratory or neurological disease
  • Diabetes mellitus
  • BMI>32, BMI<18
  • Use of vasoactive medication
  • Use of heparin or warfarin
  • Allergy/intolerance to study substance ingredients

STABLE CARDIOVASCULAR DISEASE GROUP

Inclusion criteria

  • Aged between 40 and 80 years
  • Previous ischaemic heart disease (any of previous myocardial infarction, coronary stent, angina), transient ischaemic attack or stroke disease or peripheral vascular disease
  • If taking a statin, dose must have been stable over preceding 2 months

Exclusion criteria

  • Uncontrolled hypertension
  • BMI>33
  • Use of heparin or warfarin
  • Allergy/intolerance to study substance ingredients

Treatment and study plan

Ateronon

Dietary Supplement

Tomato extract (lycopene) capsule, taken once daily for 56 days

Placebo

Dietary Supplement

Matched placebo capsule, taken once daily for 56 days

Primary outcomes

  1. Forearm blood flow ratio and/or absolute flow in the infused arm (and % change), as measured by venous occlusion plethysmography, in response to intra-arterial acetylcholine infusion.

    Time frame: 8 weeks

Secondary outcomes

  1. Forearm blood flow ratio and/or absolute flow in the infused arm (& % change), as measured by venous occlusion plethysmography, in response to intra-arterial sodium nitroprusside and L-NMMA infusion.

    Time frame: 8 weeks

  2. Evaluation of pulse wave velocity and pulse wave analysis

    Time frame: 8 weeks

  3. Pulse wave velocity measured between carotid and femoral artery.

    Time frame: 8 weeks

  4. Analysis of Lipoprotein oxidation/circulating markers.

    Time frame: 8 weeks

  5. Safety and tolerability parameters, including physical examination, blood pressure, heart rate, 12-lead electrocardiograms (ECGs), clinical laboratory tests and adverse event reporting.

    Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

Cambridge University Hospitals NHS Foundation Trust

Other

Collaborators

  • Cambridge Theranostics Ltd

Registry information

Official study title

Vascular Effects of Nutritional Supplementation With a Standardised Preparation of Tomato Extract (Ateronon) in Vivo in Man

Acronym: TomVasc

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Apr 9, 2010
Registry last updated
Jun 25, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.